Skip to search formSkip to main contentSkip to account menu

razoxane

Known as: 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+-)-, Razoxane [Chemical/Ingredient] 
An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND Chondrosarcomas and chordomas are reported to have low radio-sensitivity. Therefore, a study was undertaken to explore… 
Highly Cited
2003
Highly Cited
2003
Measurement of tumour and normal tissue perfusion in vivo in cancer patients will aid the clinical development of antiangiogenic… 
Highly Cited
2000
Highly Cited
2000
Renal cell carcinoma (RCC) is an angiogenic tumor resistant to standard cytotoxic chemotherapeutic agents. Although often… 
Highly Cited
1998
Highly Cited
1998
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis 
Highly Cited
1994
Highly Cited
1994
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… 
1986
1986
Razoxane is one of the few agents which has shown activity in the treatment of advanced colorectal cancer. The drug has therefore… 
Review
1983
Review
1983
Despite its vast utility in clinical oncology, the use of doxorubicin hydrochloride (Adriamycin) is limited by a potentially… 
1982
1982
: In this multi-institutional study of advanced gastric cancer, 73 patients were evaluable for response or survival. Patients… 
1981
1981
A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg…